Endothelial Dysfunction in Chronic Renal Failure

Journal of Renal Nutrition

Volumn 20, Issue 5, 2010, Pages S103-S108

  Santoro, Domenico ^a   Bellinghieri, Guido ^a   Conti, Giovanni ^a   Pazzano, Dario ^a   Satta, Ersilia ^a   Costantino, Giuseppe ^a   Savica, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943010194     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.06.010     Document Type: Article

References (50)

1. Meguid El, N.A., Bello, A.K., Chronic kidney disease: the global challenge. Lancet 365 (2005), 331–340.
2. Go, A.S., Chertow, G.M., Fan, D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
3. Stenvinkel, P., Heimbürger, O., Lindholm, B., et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15 (2000), 953–960.
4. Ritz, E., McClellan, W., Overview: increased cardiovascular risk in patients with minor renal dysfunction—an emerging issue with far-reaching consequences. J Am Soc Nephrol 15 (2004), 513–516.
5. Cozzolino, M., Brancaccio, D., Gallieni, M., et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68 (2005), 429–436.
6. Schiffrin, E.L., A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 38:Suppl 2 (2001), S3–S6.
7. Mallamaci, F., Tripepi, G., Cutrupi, S., et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67 (2005), 2330–2337.
8. Passauer, J., Pistrosch, F., Bussemaker, E., et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 16 (2005), 959–965.
9. Jin, L., Caldwell, R.B., Li-Masters, T., et al. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 58 (2007), 191–206.
10. Kielstein, J.T., Impraim, B., Simmel, S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004), 172–177.
11. Cooke, J.P., Asymmetrical dimethylarginine: the Uber marker?. Circulation 109 (2004), 1813–1818.
12. Matsuguma, K., Ueda, S., Yamagishi, S., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17 (2006), 2176–2183.
13. Kroncke, K.D., Fehsel, K., Kolb-Bachofen, V., Nitric oxide: cytotoxicity versus cytoprotection: how, why, when, and where?. Nitric Oxide 1 (1997), 107–120.
14. Gross, S.S., Wolin, N., Nitric oxide: pathophysiological mechanisms. Am Rev Physiol 57 (1995), 737–769.
15. Beckman, J.S., Beckman, T.W., Chen, J., et al. Apparent hydroxyl radical formation by peroxynitrile: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87 (1990), 1620–1624.
16. Amore, A., Emancipator, S.N., Cirina, P., et al. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells. Kidney Int 57 (2000), 1549–1559.
17. Amore, A., Coppo, R., Role of apoptosis in pathogenesis and progression of renal diseases. Nephron 86 (2000), 99–104.
18. Yamamoto, H., Tsuruoka, S., Ioka, T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 69 (2006), 1780–1785.
19. Dou, L., Jourde-Chiche, N., Faure, V., et al. The uremic solute indoxyl sulphate induces oxidative stress in endothelial cells. J Thromb Haemost 5 (2007), 1302–1308.
20. Kaysen, G.A., Eiserich, J.P., The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15 (2004), 538–548.
21. Williams, M.E., New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 41:3 Suppl 2 (2003), S42–S47.
22. Raj, D.S., Choudhury, D., Welbourne, T.C., et al. Advanced glycation end-products: a nephrologist's perspective. Am J Kidney Dis 35 (2000), 365–380.
23. Amore, A., Cirina, P., Conti, G., et al. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 19 (2004), 53–60.
24. Linden, E., Cai, W., He, J.C., et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 3 (2008), 691–698.
25. Satriano, J., Schlondorff, D., Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor, immunoglobulin G and cAMP. Evidence for involvement of reactive oxygen species. J Clin Invest 94 (1994), 1629–1636.
26. Serradell, M., Diaz-Ricart, M., Cases, A., et al. Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. Haematologica 87 (2002), 1053–1061.
27. Trevisan, R., Dodesini, A.R., Lepore, G., Lipids and renal disease. J Am Soc Nephrol 17 (2006), S145–S147.
28. Anagnostoulis, S., Karayiannakis, A.J., Lambropoulou, M., et al. Human leptin induces angiogenesis in vivo. Cytokine 42 (2008), 353–357.
29. Vanholder, R., Van Laecke, S., Glorieux, G., What is new in uremic toxicity?. Pediatr Nephrol 23 (2008), 1211–1221.
30. Kubo, A., Fukuda, N., Soma, M., et al. Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 27 (1996), 58–63.
31. Yanagitani, Y., Rakugi, H., Okamura, A., et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 33 (1999), 335–339.
32. Nanayakkara, P.W., van Guldener, C., ter Wee, P.M., et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167 (2007), 1262–1270.
33. Laurent, S., Boutouyrie, P., Asmar, R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001), 1236–1241.
34. Townsend, R.R., Wimmer, N.J., Chirinos, J.A., et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 23 (2010), 282–289.
35. Fantin, F., Mattoccks, A., Bulpitt, C.Q., et al. Is augmentation index a good measure of vascular stiffness in the elderly?. Age Ageing 37 (2007), 43–48.
36. Salvi, P., Magnani, E., Valbusa, F., et al. Comparative study of methodologies for pulse wave velocity estimation. J Hum Hypertens 22 (2008), 669–677.
37. Hsu, P., Yu, W., Lin, I., et al. Differential effects of age on carotid augmentation index and aortic pulse wave velocity in end stage renal disease patients. J Chin Med Assoc 71 (2008), 166–173.
38. Kawamoto, R., Kohara, K., Tabara, Y., et al. An association between decreased estimated glomerular filtration rate and arterial stiffness. Intern Med 47 (2008), 593–598.
39. Schillaci, G., Pirro, M., Mannarino, M.R., et al. Relation between renal function within the normal range and central and peripheral arterial stiffness in hypertension. Hypertension 48 (2006), 616–621.
40. Kohara, K., Tabara, Y., Tachibana, R., et al. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res 27 (2004), 471–477.
41. Vasa, M., Fichtlscherer, S., Adler, K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001), 2885–2890.
42. Werner, N., Nickenig, G., Endothelial progenitor cells in health and atherosclerotic disease. Ann Med 39 (2007), 82–89.
43. De Groot, K., Hermann, B.F., Sowa, J., et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 66 (2004), 641–646.
44. Choi, J.H., Kim, K.L., Huh, W., et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 (2004), 1246–1252.
45. Simper, D., Stalboerger, P.G., Panetta, C.J., et al. Smooth muscle progenitor cells in human blood. Circulation 106 (2002), 1199–1204.
46. Westerweel, P.E., Hoefer, I.E., Blankestijn, P.J., et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 292 (2007), F1132–F1140.
47. Cornacchia, F., Fornoni, A., Plati, A.R., et al. Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. J Clin Invest 108 (2001), 1649–1656.
48. Heeschen, C., Aicher, A., Lehmann, R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003), 1340–1346.
49. Szmitko, P.E., Fedak, P.W., Weisel, R.D., et al. Endothelial progenitor cells: new hope for a broken heart. Circulation 107 (2003), 3093–3100.
50. Li, B., Morioka, T., Uchiyama, M., et al. Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model. Kidney Int 69 (2006), 323–330.